ImageneBio Inc (IMA) vs Zhengye Biotechnology Holding Limited (ZYBT)
A side-by-side comparison of ImageneBio Inc and Zhengye Biotechnology Holding Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMA
ImageneBio Inc
$4.70HealthcareDelayed quote: Oct 6, 2026, 3:03 PM EDT
ZYBT
Zhengye Biotechnology Holding Limited
$1.13HealthcareDelayed quote: Oct 6, 2026, 3:03 PM EDT
Total return — IMA vs ZYBT
growth of $100 · dividends reinvested · last 2yIMA -76.4% (-51.4%/yr)ZYBT -75.5% (-50.5%/yr)ZYBT compounded faster over this window
IMA ZYBT
IMA vs ZYBT: by the numbers
- •ZYBT is the larger company ($54M vs $53M market cap).
- •Both run net losses; ZYBT's is the smaller (-59.97% vs -5668.62% net margin).
Metrics side by side
Valuation
| Metric | IMA | ZYBT |
|---|---|---|
| P/B ratio | 0.37 | 1.50 |
Profitability
| Metric | IMA | ZYBT |
|---|---|---|
| Gross margin | -29.12% | 20.51% |
| Operating margin | -6056.37% | -58.66% |
| Net margin | -5668.62% | -59.97% |
| ROE | -36.94% | -27.93% |
| ROIC | -40.53% | -17.88% |
Growth (annualized)
| Metric | IMA | ZYBT |
|---|---|---|
| Total return CAGR (5Y) | -50.73% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.